HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

被引：0
|
作者：
François Cherifi
Angélique Da Silva
Alison Johnson
Cécile Blanc-Fournier
Olivia Abramovici
Antonin Broyelle
Christelle Levy
Djelila Allouache
Ioana Hrab
Carine Segura
Adeline Morel
Maud Villemin
Clémence Boscher
Coraline Dubot-Poitelon
Pauline Rottier
Justine Lequesne
George Emile
机构：
[1] CLCC Francois Baclesse,Department of Clinical Research
[2] CLCC François Baclesse,Breast Cancer Unit
[3] Institut Normand du Sein,Department of Pathology
[4] CLCC Francois Baclesse,Department of Pathology
[5] CLCC Oscar Lambret,Breast Cancer Unit
[6] CLCC Oscar Lambret,undefined
来源：
BMC Cancer | / 22卷
关键词：
Antibody–drug conjugates; HER2-low; Breast cancer; Trastuzumab–deruxtecan; Neoadjuvant treatment; Lymphocytes; Neutrophils;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, Francois
    Da Silva, Angelique
    Johnson, Alison
    Blanc-Fournier, Cecile
    Abramovici, Olivia
    Broyelle, Antonin
    Levy, Christelle
    Allouache, Djelila
    Hrab, Ioana
    Segura, Carine
    Morel, Adeline
    Villemin, Maud
    Boscher, Clemence
    Dubot-Poitelon, Coraline
    Rottier, Pauline
    Lequesne, Justine
    Emile, George
    BMC CANCER, 2022, 22 (01)
  • [2] HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
    Cherifi, F.
    Da Silva, A.
    Johnson, A. C.
    Fournier, C. Blanc
    Broyelle, A.
    Abramovici, O.
    Morel, A.
    Bertho, M.
    Hrab, I.
    Allouache, D.
    Djezzer, C. Segura
    Levy, C.
    Boscher, C.
    Villemin, M.
    Rottier, P.
    Lequesne, J.
    Emile, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S172 - S172
  • [3] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [4] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [5] Clinical outcomes of neoadjuvant chemotherapy in HER2-low early breast cancer
    Gudelj, Dora
    Cular, Katarina
    Toula, Lea
    Krizic, Marija
    Popovic, Marina
    Plavetic, Natalija Dedic
    Kelecic, Ana
    Ivanac, Gordana
    Soce, Majana
    Gjergjaj, Iva Kukal
    Silovski, Tajana
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
    Shao, Yingbo
    Guan, Huijuan
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Chen, Qi
    Liu, Chaojun
    Zhu, Fangyuan
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [7] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Ilie, Silvia Mihaela
    Briot, Nathalie
    Constantin, Guillaume
    Roussot, Nicolas
    Ilie, Alis
    Bergeron, Anthony
    Arnould, Laurent
    Beltjens, Francoise
    Desmoulin, Isabelle
    Mayeur, Didier
    Kaderbhai, Coureche
    Hennequin, Audrey
    Jankowski, Clementine
    Padeano, Marie Martine
    Costaz, Helene
    Amet, Alix
    Coutant, Charles
    Coudert, Bruno
    Bertaut, Aurelie
    Ladoire, Sylvain
    BREAST CANCER, 2023, 30 (06) : 997 - 1007
  • [8] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Silvia Mihaela Ilie
    Nathalie Briot
    Guillaume Constantin
    Nicolas Roussot
    Alis Ilie
    Anthony Bergeron
    Laurent Arnould
    Françoise Beltjens
    Isabelle Desmoulin
    Didier Mayeur
    Courèche Kaderbhai
    Audrey Hennequin
    Clémentine Jankowski
    Marie Martine Padeano
    Helène Costaz
    Alix Amet
    Charles Coutant
    Bruno Coudert
    Aurélie Bertaut
    Sylvain Ladoire
    Breast Cancer, 2023, 30 : 997 - 1007
  • [9] Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer
    da Silva, Leonardo Roberto
    Sartori, Guilherme
    Ramalho, Susana
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Mantovani, Higor
    Vasconcelos, Vivian
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Barrios, Carlos
    Graudenz, Marcia Silveira
    Cabello, Cesar
    CANCER RESEARCH, 2024, 84 (09)
  • [10] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
12345